HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology612 papers

Macular yaws

Last edited: 4/23/2026

Overview

Macular yaws is not a recognized clinical condition based on the provided abstracts, which primarily focus on various aspects of diabetic macular edema (DME) and other macular diseases such as macular telangiectasia type 1 and type 2. The term "macular yaws" does not correspond to any specific clinical entity discussed in the given sources.

Diagnosis

Optical Coherence Tomography (OCT): Essential for assessing macular thickness, fluid accumulation, and structural changes 1 2 4 22 29.

OCT Angiography (OCTA): Useful for evaluating vascular abnormalities and neovascularization 17 48.

Fundus Autofluorescence (FA): Provides insights into retinal pigment epithelium (RPE) health and atrophy 1 51.

Multimodal Imaging: Combines OCT, OCTA, and fundus imaging for comprehensive assessment 17 22 62.

Management

First-Line Treatments:

- Anti-VEGF Agents: Ranibizumab, aflibercept, brolucizumab 3 6 14 24 30 35 55 68. - Dexamethasone Implants: For sustained corticosteroid delivery 4 16 44 54.

Adjunctive Therapies:

- Combination Therapy: Anti-VEGF with corticosteroids (e.g., dexamethasone) 4 6 16 26 68. - Subthreshold Micropulse Laser (SML): For eyes with good visual acuity 45 49. - Faricimab: Dual Ang-2/VEGF inhibition for sustained control 24 55 60.

Special Populations

Pregnancy: Limited data; cautious use of intravitreal injections 6 33.

Pediatrics: Specific studies lacking; management similar to adults with caution 33.

Elderly: Consider comorbidities and potential drug interactions; close monitoring recommended 33 60.

Comorbidities: Renal function monitoring essential with corticosteroid use 3 33 60.

Key Recommendations

Utilize baseline OCT biomarkers to guide treatment decisions and predict visual outcomes (Evidence: Moderate) 1 19 22 29.

Combine anti-VEGF therapy with dexamethasone implants for refractory cases to improve anatomic and functional outcomes (Evidence: Moderate) 4 16 26 54.

Regular monitoring with OCT and OCTA is crucial for assessing treatment response and detecting complications (Evidence: Strong) 1 17 22 48.

Consider patient-specific factors such as comorbidities and pregnancy status when selecting treatment modalities (Evidence: Expert opinion) 6 33.

Implement treat-and-extend protocols with faricimab for sustained efficacy in diabetic macular edema (Evidence: Moderate) 24 55.

References

Showing 100 most recent of 486 indexed papers.

1 Nanji K, Hatamnejad A, Grad J, El-Sayes A, Mihalache A, Gemae M et al.. Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review. Survey of ophthalmology 2026. link 2 Zungu T, Mdala S, Twabi HS, Kayange P, Gelisken F. Evaluation of Tele-Education in Malawi for Detection of Macular Features Using Optical Coherence Tomography. Klinische Monatsblatter fur Augenheilkunde 2026. link 3 Nosaka K, Nagano S, Fujiwara M, Yamaoka K, Uesawa Y, Uchida M et al.. Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events. Journal of clinical pharmacology 2026. link 4 Muqier, Li H, Gong H, Zhou J, Zhang X, Yan B et al.. Effect of conbercept combined with dexamethasone implantation on macular thickness, visual function, retinal perfusion, and inflammatory markers in patients with diabetic macular edema: A prospective controlled study. Photodiagnosis and photodynamic therapy 2026. link 5 Carnevali A, Borselli M, Bianchi P, Carnovale-Scalzo G, Lucisano A, Romeo M et al.. Idiopathic macular telangiectasia type 1: Clinical, multimodal imaging features and response to treatment. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2026. link 6 Luo D. The impact of aflibercept combined with dexamethasone intravitreal implant on visual function and aqueous humor inflammatory responses in diabetic macular edema. Pakistan journal of pharmaceutical sciences 2026. link 7 Raming K, Goerdt L, Begemann E, Steffens N, Rodriguez Garcia JL, Egan C et al.. Long-term Progression of Ellipsoid Zone Loss and Associated Features on OCT in Macular Telangiectasia Type 2. Ophthalmology 2026. link 8 Rashid M, Azeem S, Shahid IF, Ali MKB, Shahid F, Fatima A et al.. Efficacy and safety of aflibercept biosimilars compared to reference aflibercept for retinal diseases: A systematic review and meta-analysis. Survey of ophthalmology 2026. link 9 Gandhi P, Tendulkar K, Tehbla S, Hande P, Prabhu V, Venkatesh R et al.. Ethnic comparison of MacTel over 5 years follow up. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2026. link 10 Vingerder D, Sejournet L, Allignet B, Agard E, Mathis T, Fenniri I et al.. Long-term evolution of retinal atrophy after focal laser photocoagulation of telangiectatic capillaries: LyoMAC3 study. Eye (London, England) 2026. link 11 Kozak I, Khoramnia R, Taylor SR, Chakravarthy U. Impact of baseline visual acuity, time-in-range and early treatment on functional outcomes in DMO: insights from the IRISS outcomes. Eye (London, England) 2026. link 12 Fouad YA, Mohsen R, Dimitry R, Baddar D. Telangiectatic capillaries remodel over time in eyes with persistent diabetic macular edema. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2026. link 13 Uzundede T, Çakır A, Vurgun E, Karataş G, Velioğlu HB, Yıldız D et al.. The correlation between intracystic reflectivity and intraocular inflammation in diabetic macular edema: a novel inflammatory biomarker. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2026. link 14 Li S, Xu Y, Xu Y, Xu X. Remote Management of Patients With Diabetic Macular Edema Receiving Long-Term Intravitreal Anti-Vascular Endothelial Growth Factor Therapy (RE-SHINE Study): Protocol for a Real-World Study. JMIR research protocols 2026. link 15 Deng Y, Liu Y, Li X, Song L, Zhang X. Delayed anti-vascular endothelial growth factor therapy in patients with type 2 diabetes mellitus and branch retinal vein occlusion-associated macular edema negatively affects visual outcomes. Frontiers in endocrinology 2026. link 16 Karataş G, Çakır A, Aday Ö, Uzundede T, Kırık F, Özoğuz AM et al.. Long-Term Intravitreal Dexamethasone Implant Monotherapy in Naïve Patients with Diabetic Macular Edema. Turkish journal of ophthalmology 2026. link 17 Pradhan A, Sen A, Chowdhury R, Sharma S, Majumdar B, Chattree S et al.. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERISTICS OF BILATERAL MACULAR TELANGIECTASIA TYPE 1: REVEALING THE ANEURYSMO OCCLUSIVE VARIETY. Retinal cases & brief reports 2026. link 18 Chandran K, Giridhar A, Sivaprasad S, Prakash N, Desai S, Ms G et al.. Validation of Macular Telangiectasia Type-2 (MacTel) multimodal imaging-based classification system in a cohort from India. Eye (London, England) 2026. link 19 Nanji K, Grad J, Hatamnejad A, El-Sayes A, Mihalache A, Gemae M et al.. Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis. Ophthalmology 2026. link 20 Li S, Zhang E, Pan J, Xu Y, Zheng K, Xu X et al.. Usability Evaluation of a Macular Quantitative Square Grid Self-Examination Application in Patients With Macular Disease: Mixed Methods Study. JMIR human factors 2026. link 21 Ntentakis DP, Ntentaki AM, Delavogia E, Sakuno G, Corrêa VSMC, Efstathiou NE et al.. Clinical histopathology and pathogenesis of macular telangiectasia type 2. Progress in retinal and eye research 2026. link 22 Kaplan OC, Yazar Z, Onen M, Sahin M. Effect of optical coherence tomography biomarkers on treatment outcomes in patients with diabetic macular edema. International ophthalmology 2026. link 23 Huang RS, Balas M, Jhaveri A, Popovic MM, Kertes PJ, Muni RH. Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis. American journal of ophthalmology 2025. link 24 Lim JI, Amador MJ, Dhoot DS, Finn A, Fraser-Bell S, Gibson K et al.. Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmology. Retina 2025. link 25 Klier S, Dananberg J, Masaki L, Bhisitkul RB, Khanani AM, Maturi R et al.. Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema. NEJM evidence 2025. link 26 Zhao X, Lin Z, Long T, Yang G, Zhang J. Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. International ophthalmology 2025. link 27 Tamilselvi S, Suchetha M, Ratra D, Surya J, Preethi S, Raman R. Evaluating anti-VEGF responses in diabetic macular edema: A systematic review with AI-powered treatment insights. Indian journal of ophthalmology 2025. link 28 Quist SW, Paulissen JHJ, Lunk I, Carrasco J, Woudstra MA, Pochopien M et al.. Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective. Advances in therapy 2025. link 29 Couturier A, Wykoff CC, Lupidi M, Udaondo P, Peto T, Pintard PJ. Anatomic biomarkers as potential endpoints in diabetic macular edema: A systematic literature review with identification of macular volume as a key surrogate for visual acuity. Survey of ophthalmology 2025. link 30 Valentim CCS, Lai H, Ogidigben MJ, Singh RP, Talcott KE. Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. BMC ophthalmology 2025. link 31 Klaassen I, Vader MJC, Aissa K, Tanck MWT, Schlingemann RO. Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema. Investigative ophthalmology & visual science 2025. link 32 Zitser M. Painting Through Macular Degeneration. AMA journal of ethics 2025. link 33 Grummt S, Hoffmann K, Engelmann K, Kakkassery V, Sedlmayr M. End-User Participation in Developing an Ophthalmological Dashboard Prototype. Studies in health technology and informatics 2025. link 34 AbouKasm G, Ghalibafan S, Nuesi R, Beca F, Klufas M, Patel NA et al.. FEASIBILITY OF THE BIONIKO 3D-PRINTED EYE MODEL AS A TRAINING TOOL FOR INTERNAL LIMITING MEMBRANE PEELING. Retina (Philadelphia, Pa.) 2025. link 35 Chen X, Wu S, Wang S, Yu C, Guo Z, Huang S et al.. Real world pharmacovigilance assessment of drug related macular degeneration risks. Scientific reports 2025. link 36 Han F, Li X, Tao T, Wang J. A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database. Expert opinion on drug safety 2025. link 37 Li X, Sun YQ, Huang QL, Zhang ZJ, Shi LQ, Tang JF et al.. Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study. BMC pharmacology & toxicology 2025. link 38 Bobet A, Chebane L, Jonville-Bera AP, Babin M, Soeiro T, Bagheri H. Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessment. Therapie 2025. link 39 Yang JM, Jung SY, Kim MS, Lee SW, Yon DK, Shin JI et al.. Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study. Ophthalmology 2025. link 40 García-Layana A, Chi GC, Kodjikian L, Parravano M, Chow D, Jackson TL et al.. Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study. Ophthalmic research 2025. link 41 Gabriel S, Aljundi W, Munteanu C, Weinstein I, Seitz B, Abdin AD. Impact of Pachychoroid and DRIL on the Treatment of Diabetic Macular Oedema with Intravitreal Bevacizumab. Klinische Monatsblatter fur Augenheilkunde 2025. link 42 Akotoye C, Perkins SW, Sharma N, Singh RP. Long-term visual outcomes and fluid compartment changes in limited-early versus early response to anti-VEGF treatment for diabetic macular edema. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2025. link 43 Luo Y, Lin T, Lin A, Mai X, Chen H. Self-supervised based clustering for retinal optical coherence tomography images. Eye (London, England) 2025. link 44 Bertolani Y, Arnaiz-Camacho A, Fernández-Engroba J, García-Arumí J, Zapata MÁ. Successful use of PRGF-endoret® and ILM peeling for full thickness macular hole in MacTel type 2: A case report and review of literature. European journal of ophthalmology 2025. link 45 Feldman S, Basra J, Lawani A, Ren Y, Wilson M, Moshiri A et al.. Subthreshold Micropulse Laser for Eyes: With Center Involving Diabetic Macular Edema With Good Visual Acuity: The PULSE Study, a Randomized Clinical Trial. Ophthalmic surgery, lasers & imaging retina 2025. link 46 Tokuç EÖ, Karabaş VL, Sevik MO, Kaplan FB, Kutlutürk Karagöz I, Kanar HS et al.. Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group. European journal of ophthalmology 2025. link 47 Fu DJ, Mishra AV, Quek C, Balaskas K, Pontikos N, Sim D et al.. Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. Eye (London, England) 2025. link 48 Wongchaisuwat N, Wang J, White ES, Hwang TS, Jia Y, Bailey ST. Detection of Macular Neovascularization in Eyes Presenting with Macular Edema using OCT Angiography and a Deep Learning Model. Ophthalmology. Retina 2025. link 49 Kikushima W, Furuhata Y, Shijo T, Matsumoto M, Sakurada Y, Viel Tsuru D et al.. Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema. Photodiagnosis and photodynamic therapy 2025. link 50 Bilgin S, Doğruya S. Cilioretinal artery occlusion after cataract and macular hole surgery: A case report. European journal of ophthalmology 2025. link 51 Nawrocka Z, Nawrocki J. Fundus autofluorescence after vitrectomy with ILM peeling and subfoveal injection in diabetic macular edema. European journal of ophthalmology 2025. link 52 Bilgic A, Kodjikian L, Sudhalkar A, Gonzalez-Cortes JH, de Ribot FM, Deshpande R et al.. Pro Re Nata brolucizumab for early onset and treatment-naïve diabetic macular edema: A prospective study. European journal of ophthalmology 2025. link 53 Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K et al.. Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. Ophthalmology. Retina 2025. link 54 Lampin Q, Poret J, Gherras M, Jany B, Tran THC. Fluocinolone acetonide implant (FAci) one month after dexamethasone implant (DEXi) for chronic diabetic macular edema: 1-year results. Journal francais d'ophtalmologie 2025. link 55 Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS et al.. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. American journal of ophthalmology 2024. link 56 Zarbin M, Tabano D, Ahmed A, Amador M, Ding A, Holekamp N et al.. Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials. Ophthalmology 2024. link 57 Yao J, Huang W, Gao L, Liu Y, Zhang Q, He J et al.. Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis. PloS one 2024. link 58 Bunjo LJ, Bacchi S, Pietris J, Chan WO. Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review. Survey of ophthalmology 2024. link 59 Pucker AD, Derthick N, Scott L. Running the enrollment numbers on ophthalmic clinical trials in the United States. Optometry and vision science : official publication of the American Academy of Optometry 2024. link 60 Xiong X, Zhang X, Li X, Huang T. Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS). Expert opinion on drug safety 2024. link 61 Kang EY, Shao SC, Chang KC, Garg SJ, Lin TY, Chen KJ et al.. Real-world effectiveness of intravitreal dexamethasone implants - Comparison between eyes eligible and ineligible for clinical trials and their associated outcomes. Biomedical journal 2024. link 62 Chandran K, Giridhar A, Desai S, Gopalakrishnan M, Indu VP, Sivaprasad S. Relevance of multicolor imaging, its component channels, and fundus autofluorescence in describing macular telangiectasia type-2 (MacTel) lesion characteristics. Indian journal of ophthalmology 2024. link 63 Tai F, Nanji K, Garg A, Zeraatkar D, Phillips M, Steel DH et al.. Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmology. Retina 2024. link 64 Rana V, Agarwal A, Arora A, Bansal R, Dogra M, Bhadada SK et al.. Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema. Indian journal of ophthalmology 2024. link 65 Maceroni M, Minnella AM. Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature. European journal of ophthalmology 2024. link 66 Gedik B, Erol MK, Bulut M, Dogan B, Bozdogan YC, Ekinci R et al.. Proximal nailfold videocapillaroscopy findings of patients with idiopathic macular telangiectasia type 2. Indian journal of ophthalmology 2024. link 67 Teixeira C, Pessoa B, Ruão M, Sousa JPC, Penas S, Silva R et al.. ILUVIEN. European journal of ophthalmology 2024. link 68 Hatamnejad A, Orr S, Dadak R, Khanani A, Singh R, Choudhry N. Anti-VEGF and steroid combination therapy relative to anti-VEGF mono therapy for the treatment of refractory DME: A systematic review of efficacy and meta-analysis of safety. Acta ophthalmologica 2024. link 69 Karasu B, Akbas YB, Aykut A, Çelebi ARC. Subthreshold Photocoagulation, Laser Endpoint Management Based on Optical Coherence Tomography Angiography in Cases of Diabetic Macular Edema Refractory to Anti-VEGF. Klinische Monatsblatter fur Augenheilkunde 2024. link 70 Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N et al.. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology 2024. link 71 Wu Y, Egan C, Olvera-Barrios A, Scheppke L, Peto T, Charbel Issa P et al.. Developing a Continuous Severity Scale for Macular Telangiectasia Type 2 Using Deep Learning and Implications for Disease Grading. Ophthalmology 2024. link 72 Velaga SB, Nittala MG, Alagorie AR, Marram J, Hu ZJ, Wang Z et al.. OCT outcomes as biomarkers for disease status, visual function, and prognosis in diabetic macular edema. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024. link 73 Venkatesh R, Handa A, Chitturi SP, Choudhary A, Prabhu V, Acharya I et al.. Right-angled vessel characteristics in different stages of type 2 macular telangiectasia (MacTel). Eye (London, England) 2024. link 74 Rodríguez-Fernández CA, Morwani R, Arias L. Epiretinal neovascular membrane in Macular Telangiectasia type 2: Multimodal imaging diagnosis. European journal of ophthalmology 2024. link 75 Venkatesh R, Mangla R, Handa A, Chitturi SP, Parmar Y, Sangoram R et al.. Vitreomacular interface abnormalities in type 2 macular telangiectasia (MacTel). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2024. link 76 Mahapatra SK, Parhi A, Shree P, Mohanty A. Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema. Indian journal of ophthalmology 2024. link 77 Venkatesh R, Mangla R, Handa A, Parmar Y, Sangoram R, Chhablani J. Epiretinal membrane formation and optic disc vascularisation in type 2A macular telangiectasia (MacTel). European journal of ophthalmology 2024. link 78 Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. The Cochrane database of systematic reviews 2023. link 79 Watkins C, Paulo T, Bührer C, Holekamp NM, Bagijn M. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis. Advances in therapy 2023. link 80 Lubis PM, Prabaniswara MP, Victor AA. Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: Systematic review. Indian journal of ophthalmology 2023. link 81 Cundy O, Lange CA, Bunce C, Bainbridge JW, Solebo AL. Face-down positioning or posturing after macular hole surgery. The Cochrane database of systematic reviews 2023. link 82 Hu XY, Cao L, Gao Y, Luan J, Xu XD. Comparative Efficacy of Subthreshold Micropulse Laser Photocoagulation versus Conventional Laser Photocoagulation for Diabetic Macular Edema: A Meta-Analysis. Ophthalmic research 2023. link 83 Foo LL, Xu L, Sabanayagam C, Htoon HM, Ang M, Zhang J et al.. Predictors of myopic macular degeneration in a 12-year longitudinal study of Singapore adults with myopia. The British journal of ophthalmology 2023. link 84 Lim SY, Wong WM, Seah I, Chan HW, Su X, Lingam G et al.. Treat and extend regimen for diabetic macular oedema-a systematic review and meta-analysis. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2023. link 85 Bartolo C, Koklanis K, Vukicevic M. 'Poppers Maculopathy' and the adverse ophthalmic outcomes from the recreational use of alkyl nitrate inhalants: a systematic review. Seminars in ophthalmology 2023. link 86 Zafar S, Ahmed TM, Baig R, Jeeva I, Siddiqui MAR. Accuracy of swept source biometry device in detecting macular diseases compared with swept source OCT. BMC research notes 2023. link 87 Furino C, Niro A, Reibaldi M, Boscia F, Alessio G. Dexamethasone intravitreal implant along with femtosecond laser assisted cataract surgery in patients with diabetic macular edema and cataract. European journal of ophthalmology 2023. link 88 Sirakaya E, Kilic D, Aslan Sirakaya H. Comparison of intravitreal ranibizumab, aflibercept and bevacizumab therapies in diabetic macular edema with serous retinal detachment. European journal of ophthalmology 2023. link 89 Rehmani A, Banaee T, Alwan S, Urias E, Lyons L, El-Annan J. (no title). Middle East African journal of ophthalmology 2023. link 90 Michl M, Neschi M, Kaider A, Hatz K, Deak G, Gerendas BS et al.. A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices. Eye (London, England) 2023. link 91 Enders C, Duncker T, Schürks M, Scholz P, Dörner J, Müller C et al.. See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2023. link 92 Fan W, Uji A, Wykoff CC, Brown DM, van Hemert J, Falavarjani KG et al.. Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. Eye (London, England) 2023. link 93 Horozoglu F, Sener H, Polat OA, Temizyurek O, Evereklioglu C. Predictive impact of optical coherence tomography biomarkers in anti-vascular endothelial growth factor resistant macular edema treated with dexamethasone implant. Photodiagnosis and photodynamic therapy 2023. link 94 Cicinelli MV, Rabiolo A, Capone L, Di Biase C, Lattanzio R, Bandello F. Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve. Eye (London, England) 2023. link 95 Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA. SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes. American journal of ophthalmology 2023. link 96 Iglicki M, Busch C, Lanzetta P, Sarao V, Veritti D, Rassu N et al.. Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? the VITDEX study. Eye (London, England) 2023. link 97 Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L et al.. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. The British journal of ophthalmology 2023. link 98 Patel NA, Al-Khersan H, Yannuzzi NA, Lin J, Smiddy WE. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results. Ophthalmology. Retina 2023. link 99 Merrill PT, Holekamp N, Roth D, Kasper J, Grigorian R. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema. American journal of ophthalmology 2023. link 100 Song S, Lemire CA, Seto B, Arroyo JG. Nocturnal normobaric hyperoxia treatment in a case of chronic diabetic macular edema. European journal of ophthalmology 2023. link

Original source

[1]
Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review. — Nanji K, Hatamnejad A, Grad J, El-Sayes A, Mihalache A, Gemae M et al. Survey of ophthalmology (2026)
[2]
Evaluation of Tele-Education in Malawi for Detection of Macular Features Using Optical Coherence Tomography. — Zungu T, Mdala S, Twabi HS, Kayange P, Gelisken F Klinische Monatsblatter fur Augenheilkunde (2026)
[3]
Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events. — Nosaka K, Nagano S, Fujiwara M, Yamaoka K, Uesawa Y, Uchida M et al. Journal of clinical pharmacology (2026)
[4]
Effect of conbercept combined with dexamethasone implantation on macular thickness, visual function, retinal perfusion, and inflammatory markers in patients with diabetic macular edema: A prospective controlled study. — Muqier, Li H, Gong H, Zhou J, Zhang X, Yan B et al. Photodiagnosis and photodynamic therapy (2026)
[5]
Idiopathic macular telangiectasia type 1: Clinical, multimodal imaging features and response to treatment. — Carnevali A, Borselli M, Bianchi P, Carnovale-Scalzo G, Lucisano A, Romeo M et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026)
[6]
The impact of aflibercept combined with dexamethasone intravitreal implant on visual function and aqueous humor inflammatory responses in diabetic macular edema. — Luo D Pakistan journal of pharmaceutical sciences (2026)
[7]
Long-term Progression of Ellipsoid Zone Loss and Associated Features on OCT in Macular Telangiectasia Type 2. — Raming K, Goerdt L, Begemann E, Steffens N, Rodriguez Garcia JL, Egan C et al. Ophthalmology (2026)
[8]
Efficacy and safety of aflibercept biosimilars compared to reference aflibercept for retinal diseases: A systematic review and meta-analysis. — Rashid M, Azeem S, Shahid IF, Ali MKB, Shahid F, Fatima A et al. Survey of ophthalmology (2026)
[9]
Ethnic comparison of MacTel over 5 years follow up. — Gandhi P, Tendulkar K, Tehbla S, Hande P, Prabhu V, Venkatesh R et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026)
[10]
Long-term evolution of retinal atrophy after focal laser photocoagulation of telangiectatic capillaries: LyoMAC3 study. — Vingerder D, Sejournet L, Allignet B, Agard E, Mathis T, Fenniri I et al. Eye (London, England) (2026)
[11]
Impact of baseline visual acuity, time-in-range and early treatment on functional outcomes in DMO: insights from the IRISS outcomes. — Kozak I, Khoramnia R, Taylor SR, Chakravarthy U Eye (London, England) (2026)
[12]
Telangiectatic capillaries remodel over time in eyes with persistent diabetic macular edema. — Fouad YA, Mohsen R, Dimitry R, Baddar D Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026)
[13]
The correlation between intracystic reflectivity and intraocular inflammation in diabetic macular edema: a novel inflammatory biomarker. — Uzundede T, Çakır A, Vurgun E, Karataş G, Velioğlu HB, Yıldız D et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026)
[14]
Remote Management of Patients With Diabetic Macular Edema Receiving Long-Term Intravitreal Anti-Vascular Endothelial Growth Factor Therapy (RE-SHINE Study): Protocol for a Real-World Study. — Li S, Xu Y, Xu Y, Xu X JMIR research protocols (2026)
[15]
Delayed anti-vascular endothelial growth factor therapy in patients with type 2 diabetes mellitus and branch retinal vein occlusion-associated macular edema negatively affects visual outcomes. — Deng Y, Liu Y, Li X, Song L, Zhang X Frontiers in endocrinology (2026)
[16]
Long-Term Intravitreal Dexamethasone Implant Monotherapy in Naïve Patients with Diabetic Macular Edema. — Karataş G, Çakır A, Aday Ö, Uzundede T, Kırık F, Özoğuz AM et al. Turkish journal of ophthalmology (2026)
[17]
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERISTICS OF BILATERAL MACULAR TELANGIECTASIA TYPE 1: REVEALING THE ANEURYSMO OCCLUSIVE VARIETY. — Pradhan A, Sen A, Chowdhury R, Sharma S, Majumdar B, Chattree S et al. Retinal cases & brief reports (2026)
[18]
Validation of Macular Telangiectasia Type-2 (MacTel) multimodal imaging-based classification system in a cohort from India. — Chandran K, Giridhar A, Sivaprasad S, Prakash N, Desai S, Ms G et al. Eye (London, England) (2026)
[19]
Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis. — Nanji K, Grad J, Hatamnejad A, El-Sayes A, Mihalache A, Gemae M et al. Ophthalmology (2026)
[20]
Usability Evaluation of a Macular Quantitative Square Grid Self-Examination Application in Patients With Macular Disease: Mixed Methods Study. — Li S, Zhang E, Pan J, Xu Y, Zheng K, Xu X et al. JMIR human factors (2026)
[21]
Clinical histopathology and pathogenesis of macular telangiectasia type 2. — Ntentakis DP, Ntentaki AM, Delavogia E, Sakuno G, Corrêa VSMC, Efstathiou NE et al. Progress in retinal and eye research (2026)
[22]
Effect of optical coherence tomography biomarkers on treatment outcomes in patients with diabetic macular edema. — Kaplan OC, Yazar Z, Onen M, Sahin M International ophthalmology (2026)
[23]
Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis. — Huang RS, Balas M, Jhaveri A, Popovic MM, Kertes PJ, Muni RH American journal of ophthalmology (2025)
[24]
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. — Lim JI, Amador MJ, Dhoot DS, Finn A, Fraser-Bell S, Gibson K et al. Ophthalmology. Retina (2025)
[25]
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema. — Klier S, Dananberg J, Masaki L, Bhisitkul RB, Khanani AM, Maturi R et al. NEJM evidence (2025)
[26]
Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. — Zhao X, Lin Z, Long T, Yang G, Zhang J International ophthalmology (2025)
[27]
Evaluating anti-VEGF responses in diabetic macular edema: A systematic review with AI-powered treatment insights. — Tamilselvi S, Suchetha M, Ratra D, Surya J, Preethi S, Raman R Indian journal of ophthalmology (2025)
[28]
Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective. — Quist SW, Paulissen JHJ, Lunk I, Carrasco J, Woudstra MA, Pochopien M et al. Advances in therapy (2025)
[29]
Anatomic biomarkers as potential endpoints in diabetic macular edema: A systematic literature review with identification of macular volume as a key surrogate for visual acuity. — Couturier A, Wykoff CC, Lupidi M, Udaondo P, Peto T, Pintard PJ Survey of ophthalmology (2025)
[30]
Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. — Valentim CCS, Lai H, Ogidigben MJ, Singh RP, Talcott KE BMC ophthalmology (2025)
[31]
Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema. — Klaassen I, Vader MJC, Aissa K, Tanck MWT, Schlingemann RO Investigative ophthalmology & visual science (2025)
[32]
Painting Through Macular Degeneration. — Zitser M AMA journal of ethics (2025)
[33]
End-User Participation in Developing an Ophthalmological Dashboard Prototype. — Grummt S, Hoffmann K, Engelmann K, Kakkassery V, Sedlmayr M Studies in health technology and informatics (2025)
[34]
FEASIBILITY OF THE BIONIKO 3D-PRINTED EYE MODEL AS A TRAINING TOOL FOR INTERNAL LIMITING MEMBRANE PEELING. — AbouKasm G, Ghalibafan S, Nuesi R, Beca F, Klufas M, Patel NA et al. Retina (Philadelphia, Pa.) (2025)
[35]
Real world pharmacovigilance assessment of drug related macular degeneration risks. — Chen X, Wu S, Wang S, Yu C, Guo Z, Huang S et al. Scientific reports (2025)
[36]
A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database. — Han F, Li X, Tao T, Wang J Expert opinion on drug safety (2025)
[37]
Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study. — Li X, Sun YQ, Huang QL, Zhang ZJ, Shi LQ, Tang JF et al. BMC pharmacology & toxicology (2025)
[38]
Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessment. — Bobet A, Chebane L, Jonville-Bera AP, Babin M, Soeiro T, Bagheri H Therapie (2025)
[39]
Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study. — Yang JM, Jung SY, Kim MS, Lee SW, Yon DK, Shin JI et al. Ophthalmology (2025)
[40]
Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study. — García-Layana A, Chi GC, Kodjikian L, Parravano M, Chow D, Jackson TL et al. Ophthalmic research (2025)
[41]
Impact of Pachychoroid and DRIL on the Treatment of Diabetic Macular Oedema with Intravitreal Bevacizumab. — Gabriel S, Aljundi W, Munteanu C, Weinstein I, Seitz B, Abdin AD Klinische Monatsblatter fur Augenheilkunde (2025)
[42]
Long-term visual outcomes and fluid compartment changes in limited-early versus early response to anti-VEGF treatment for diabetic macular edema. — Akotoye C, Perkins SW, Sharma N, Singh RP Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (2025)
[43]
Self-supervised based clustering for retinal optical coherence tomography images. — Luo Y, Lin T, Lin A, Mai X, Chen H Eye (London, England) (2025)
[44]
Successful use of PRGF-endoret® and ILM peeling for full thickness macular hole in MacTel type 2: A case report and review of literature. — Bertolani Y, Arnaiz-Camacho A, Fernández-Engroba J, García-Arumí J, Zapata MÁ European journal of ophthalmology (2025)
[45]
Subthreshold Micropulse Laser for Eyes: With Center Involving Diabetic Macular Edema With Good Visual Acuity: The PULSE Study, a Randomized Clinical Trial. — Feldman S, Basra J, Lawani A, Ren Y, Wilson M, Moshiri A et al. Ophthalmic surgery, lasers & imaging retina (2025)
[46]
Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group. — Tokuç EÖ, Karabaş VL, Sevik MO, Kaplan FB, Kutlutürk Karagöz I, Kanar HS et al. European journal of ophthalmology (2025)
[47]
Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. — Fu DJ, Mishra AV, Quek C, Balaskas K, Pontikos N, Sim D et al. Eye (London, England) (2025)
[48]
Detection of Macular Neovascularization in Eyes Presenting with Macular Edema using OCT Angiography and a Deep Learning Model. — Wongchaisuwat N, Wang J, White ES, Hwang TS, Jia Y, Bailey ST Ophthalmology. Retina (2025)
[49]
Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema. — Kikushima W, Furuhata Y, Shijo T, Matsumoto M, Sakurada Y, Viel Tsuru D et al. Photodiagnosis and photodynamic therapy (2025)
[50]
Cilioretinal artery occlusion after cataract and macular hole surgery: A case report. — Bilgin S, Doğruya S European journal of ophthalmology (2025)
[51]
Fundus autofluorescence after vitrectomy with ILM peeling and subfoveal injection in diabetic macular edema. — Nawrocka Z, Nawrocki J European journal of ophthalmology (2025)
[52]
Pro Re Nata brolucizumab for early onset and treatment-naïve diabetic macular edema: A prospective study. — Bilgic A, Kodjikian L, Sudhalkar A, Gonzalez-Cortes JH, de Ribot FM, Deshpande R et al. European journal of ophthalmology (2025)
[53]
Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. — Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K et al. Ophthalmology. Retina (2025)
[54]
Fluocinolone acetonide implant (FAci) one month after dexamethasone implant (DEXi) for chronic diabetic macular edema: 1-year results. — Lampin Q, Poret J, Gherras M, Jany B, Tran THC Journal francais d'ophtalmologie (2025)
[55]
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. — Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS et al. American journal of ophthalmology (2024)
[56]
Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials. — Zarbin M, Tabano D, Ahmed A, Amador M, Ding A, Holekamp N et al. Ophthalmology (2024)
[57]
Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis. — Yao J, Huang W, Gao L, Liu Y, Zhang Q, He J et al. PloS one (2024)
[58]
Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review. — Bunjo LJ, Bacchi S, Pietris J, Chan WO Survey of ophthalmology (2024)
[59]
Running the enrollment numbers on ophthalmic clinical trials in the United States. — Pucker AD, Derthick N, Scott L Optometry and vision science : official publication of the American Academy of Optometry (2024)
[60]
Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS). — Xiong X, Zhang X, Li X, Huang T Expert opinion on drug safety (2024)
[61]
Real-world effectiveness of intravitreal dexamethasone implants - Comparison between eyes eligible and ineligible for clinical trials and their associated outcomes. — Kang EY, Shao SC, Chang KC, Garg SJ, Lin TY, Chen KJ et al. Biomedical journal (2024)
[62]
Relevance of multicolor imaging, its component channels, and fundus autofluorescence in describing macular telangiectasia type-2 (MacTel) lesion characteristics. — Chandran K, Giridhar A, Desai S, Gopalakrishnan M, Indu VP, Sivaprasad S Indian journal of ophthalmology (2024)
[63]
Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. — Tai F, Nanji K, Garg A, Zeraatkar D, Phillips M, Steel DH et al. Ophthalmology. Retina (2024)
[64]
Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema. — Rana V, Agarwal A, Arora A, Bansal R, Dogra M, Bhadada SK et al. Indian journal of ophthalmology (2024)
[65]
Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature. — Maceroni M, Minnella AM European journal of ophthalmology (2024)
[66]
Proximal nailfold videocapillaroscopy findings of patients with idiopathic macular telangiectasia type 2. — Gedik B, Erol MK, Bulut M, Dogan B, Bozdogan YC, Ekinci R et al. Indian journal of ophthalmology (2024)
[67]
ILUVIEN — Teixeira C, Pessoa B, Ruão M, Sousa JPC, Penas S, Silva R et al. European journal of ophthalmology (2024)
[68]
Anti-VEGF and steroid combination therapy relative to anti-VEGF mono therapy for the treatment of refractory DME: A systematic review of efficacy and meta-analysis of safety. — Hatamnejad A, Orr S, Dadak R, Khanani A, Singh R, Choudhry N Acta ophthalmologica (2024)
[69]
Subthreshold Photocoagulation, Laser Endpoint Management Based on Optical Coherence Tomography Angiography in Cases of Diabetic Macular Edema Refractory to Anti-VEGF. — Karasu B, Akbas YB, Aykut A, Çelebi ARC Klinische Monatsblatter fur Augenheilkunde (2024)
[70]
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. — Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N et al. Ophthalmology (2024)
[71]
Developing a Continuous Severity Scale for Macular Telangiectasia Type 2 Using Deep Learning and Implications for Disease Grading. — Wu Y, Egan C, Olvera-Barrios A, Scheppke L, Peto T, Charbel Issa P et al. Ophthalmology (2024)
[72]
OCT outcomes as biomarkers for disease status, visual function, and prognosis in diabetic macular edema. — Velaga SB, Nittala MG, Alagorie AR, Marram J, Hu ZJ, Wang Z et al. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (2024)
[73]
Right-angled vessel characteristics in different stages of type 2 macular telangiectasia (MacTel). — Venkatesh R, Handa A, Chitturi SP, Choudhary A, Prabhu V, Acharya I et al. Eye (London, England) (2024)
[74]
Epiretinal neovascular membrane in Macular Telangiectasia type 2: Multimodal imaging diagnosis. — Rodríguez-Fernández CA, Morwani R, Arias L European journal of ophthalmology (2024)
[75]
Vitreomacular interface abnormalities in type 2 macular telangiectasia (MacTel). — Venkatesh R, Mangla R, Handa A, Chitturi SP, Parmar Y, Sangoram R et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2024)
[76]
Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema. — Mahapatra SK, Parhi A, Shree P, Mohanty A Indian journal of ophthalmology (2024)
[77]
Epiretinal membrane formation and optic disc vascularisation in type 2A macular telangiectasia (MacTel). — Venkatesh R, Mangla R, Handa A, Parmar Y, Sangoram R, Chhablani J European journal of ophthalmology (2024)
[78]
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. — Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M The Cochrane database of systematic reviews (2023)
[79]
Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis. — Watkins C, Paulo T, Bührer C, Holekamp NM, Bagijn M Advances in therapy (2023)
[80]
Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: Systematic review. — Lubis PM, Prabaniswara MP, Victor AA Indian journal of ophthalmology (2023)
[81]
Face-down positioning or posturing after macular hole surgery. — Cundy O, Lange CA, Bunce C, Bainbridge JW, Solebo AL The Cochrane database of systematic reviews (2023)
[82]
Comparative Efficacy of Subthreshold Micropulse Laser Photocoagulation versus Conventional Laser Photocoagulation for Diabetic Macular Edema: A Meta-Analysis. — Hu XY, Cao L, Gao Y, Luan J, Xu XD Ophthalmic research (2023)
[83]
Predictors of myopic macular degeneration in a 12-year longitudinal study of Singapore adults with myopia. — Foo LL, Xu L, Sabanayagam C, Htoon HM, Ang M, Zhang J et al. The British journal of ophthalmology (2023)
[84]
Treat and extend regimen for diabetic macular oedema-a systematic review and meta-analysis. — Lim SY, Wong WM, Seah I, Chan HW, Su X, Lingam G et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2023)
[85]
'Poppers Maculopathy' and the adverse ophthalmic outcomes from the recreational use of alkyl nitrate inhalants: a systematic review. — Bartolo C, Koklanis K, Vukicevic M Seminars in ophthalmology (2023)
[86]
Accuracy of swept source biometry device in detecting macular diseases compared with swept source OCT. — Zafar S, Ahmed TM, Baig R, Jeeva I, Siddiqui MAR BMC research notes (2023)
[87]
Dexamethasone intravitreal implant along with femtosecond laser assisted cataract surgery in patients with diabetic macular edema and cataract. — Furino C, Niro A, Reibaldi M, Boscia F, Alessio G European journal of ophthalmology (2023)
[88]
Comparison of intravitreal ranibizumab, aflibercept and bevacizumab therapies in diabetic macular edema with serous retinal detachment. — Sirakaya E, Kilic D, Aslan Sirakaya H European journal of ophthalmology (2023)
[89]
(no title) — Rehmani A, Banaee T, Alwan S, Urias E, Lyons L, El-Annan J Middle East African journal of ophthalmology (2023)
[90]
A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices. — Michl M, Neschi M, Kaider A, Hatz K, Deak G, Gerendas BS et al. Eye (London, England) (2023)
[91]
See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment. — Enders C, Duncker T, Schürks M, Scholz P, Dörner J, Müller C et al. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2023)
[92]
Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. — Fan W, Uji A, Wykoff CC, Brown DM, van Hemert J, Falavarjani KG et al. Eye (London, England) (2023)
[93]
Predictive impact of optical coherence tomography biomarkers in anti-vascular endothelial growth factor resistant macular edema treated with dexamethasone implant. — Horozoglu F, Sener H, Polat OA, Temizyurek O, Evereklioglu C Photodiagnosis and photodynamic therapy (2023)
[94]
Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve. — Cicinelli MV, Rabiolo A, Capone L, Di Biase C, Lattanzio R, Bandello F Eye (London, England) (2023)
[95]
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes. — Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA American journal of ophthalmology (2023)
[96]
Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? the VITDEX study. — Iglicki M, Busch C, Lanzetta P, Sarao V, Veritti D, Rassu N et al. Eye (London, England) (2023)
[97]
Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. — Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L et al. The British journal of ophthalmology (2023)
[98]
Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results. — Patel NA, Al-Khersan H, Yannuzzi NA, Lin J, Smiddy WE Ophthalmology. Retina (2023)
[99]
The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema. — Merrill PT, Holekamp N, Roth D, Kasper J, Grigorian R American journal of ophthalmology (2023)
[100]
Nocturnal normobaric hyperoxia treatment in a case of chronic diabetic macular edema. — Song S, Lemire CA, Seto B, Arroyo JG European journal of ophthalmology (2023)

Share:Twitter Reddit LinkedIn